RE-CELLULARIZATION VIA ELECTROPORATION THERAPY (RECET) COMBINED WITH GLP-1RA TO REPLACE INSULIN THERAPY IN PATIENTS WITH TYPE 2 DIABETES 6 MONTHS RESULTS OF THE EMINENT STUDY

被引：0
|
作者：
Busch, Celine [1 ]
Meiring, Suzanne [1 ]
Van Baar, Annieke [1 ]
Holleman, Frits [1 ]
Nieuwdorp, Max [1 ]
Bergman, Jacques [1 ]
机构：
[1] Amsterdam UMC Locatie AMC, Amsterdam, Netherlands
来源：
GASTROINTESTINAL ENDOSCOPY | 2023年 / 97卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1272
引用
收藏
页码：AB760 / AB760
页数：1
相关论文
共 50 条
  • [21] Glycaemic control and beta cell function in type 2 diabetes on SGLT2i and GLP-1RA combination therapy
    Martinez, R.
    Al-Jobory, H.
    Adams, J.
    Chavez-Velasquez, A.
    Triplitt, C.
    DeFronzo, R. A.
    Cersosimo, E.
    DIABETOLOGIA, 2017, 60 : S408 - S409
  • [22] GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen
    Davies, Marie L.
    Pham, David Q.
    Drab, Scott R.
    PHARMACOTHERAPY, 2016, 36 (08): : 893 - 905
  • [23] Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy
    Dave, Chintan V.
    Kim, Seoyoung C.
    Goldfine, Allison B.
    Glynn, Robert J.
    Tong, Angela
    Patorno, Elisabetta
    CIRCULATION, 2021, 143 (08) : 770 - 779
  • [24] Deintensification of basal-bolus insulin after initiation of GLP-1RA in patients with type 2 diabetes under routine care
    Bonora, Benedetta Maria
    Rigato, Mauro
    Frison, Vera
    D'Ambrosio, Michele
    Tadiotto, Federica
    Lapolla, Annunziata
    Simioni, Natalino
    Paccagnella, Agostino
    Avogaro, Angelo
    Fadini, Gian Paolo
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 173
  • [25] GLP-1RA Therapy Recovers Vascular Regenerative Cell Content in High Cardiovascular-Risk Individuals with Type 2 Diabetes
    Krishnaraj, Aishwarya
    Park, Brady
    Bakbak, Ehab
    Verma, Raj
    Quan, Adrian
    Teoh, Hwee
    Hess, David A.
    Verma, Subodh
    DIABETES, 2024, 73
  • [26] Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection
    Andreasen, Christine Rode
    Andersen, Andreas
    Knop, Filip Krag
    Vilsboll, Tina
    DIABETES OBESITY & METABOLISM, 2021, 23 : 40 - 52
  • [27] Insulin pump therapy from diagnosis of type 1 diabetes - Results from the first 6 months
    Ramchandani, N
    Ten, S
    Kamishlian, A
    Anhalt, H
    Kukreja, A
    Maclaren, N
    DIABETES, 2003, 52 : A439 - A439
  • [28] LONG-TERM HEPATOPROTECTIVE EFFECTS OF GLP-1RA IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY
    Khataniar, Himsikhar
    Dharia, Ashni
    Desai, Aakash
    Butt, Muhammad Ali
    Babich, Michael
    Mohy-ud-din, Nabeeha
    HEPATOLOGY, 2024, 80
  • [29] Adherence to Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Therapy in Patients with Type 2 Diabetes Mellitus (T2DM)
    Johnston, Stephen
    Nguyen, Hiep
    Felber, Eugene
    Cappell, Katherine
    Nelson, James K.
    Chu, Bong-Chul
    Kalsekar, Iftekhar
    DIABETES, 2014, 63 : A604 - A604
  • [30] Duodenal Mucosal Resurfacing (DMR) Combined with GLP-1 RA May Eliminate Insulin Therapy and Improve Metabolic Health in Type 2 Diabetes
    Smeele, Paul
    Van Baar, Annieke C.
    Vriend, Tessa M.
    Vriend, Tessa M.
    Holleman, Frits
    Soeters, Maarten
    Nieuwdorp, Max
    Tijssen, Jan
    Bergman, Jacques J.
    DIABETES, 2019, 68
12345